Ravindra Rampariag , Igor Chernyavskiy , Mohammad Al-Ajam , Jun-Chieh J. Tsay
{"title":"Controversies and challenges in lung cancer screening","authors":"Ravindra Rampariag , Igor Chernyavskiy , Mohammad Al-Ajam , Jun-Chieh J. Tsay","doi":"10.1053/j.seminoncol.2022.07.002","DOIUrl":null,"url":null,"abstract":"<div><p>Two large randomized controlled trials have shown mortality benefit from lung cancer screening (LCS) in high-risk groups. Updated guidelines by the United State Preventative Service Task Force in 2020 will allow for inclusion of more patients who are at high risk of developing lung cancer and benefit from screening. As medical clinics and lung cancer screening programs around the country continue to work on perfecting the LCS workflow, it is important to understand some controversial issues surrounding LCS that should be addressed. In this article, we identify some of these issues, including false positive rates of low-dose CT, over-diagnosis, cost expenditure, LCS disparities in minorities, and utility of biomarkers. We hope to provide clarity, potential solutions, and future directions on how to address these controversies.</p></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"49 3","pages":"Pages 191-197"},"PeriodicalIF":3.0000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0093775422000562/pdfft?md5=7490a688638850a3721d3503cf457ed0&pid=1-s2.0-S0093775422000562-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0093775422000562","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Two large randomized controlled trials have shown mortality benefit from lung cancer screening (LCS) in high-risk groups. Updated guidelines by the United State Preventative Service Task Force in 2020 will allow for inclusion of more patients who are at high risk of developing lung cancer and benefit from screening. As medical clinics and lung cancer screening programs around the country continue to work on perfecting the LCS workflow, it is important to understand some controversial issues surrounding LCS that should be addressed. In this article, we identify some of these issues, including false positive rates of low-dose CT, over-diagnosis, cost expenditure, LCS disparities in minorities, and utility of biomarkers. We hope to provide clarity, potential solutions, and future directions on how to address these controversies.
两项大型随机对照试验显示，高风险人群肺癌筛查(LCS)可降低死亡率。美国预防服务工作组(United states preventive Service Task Force)在2020年更新的指南将允许纳入更多患肺癌高风险并从筛查中受益的患者。随着全国各地的医疗诊所和肺癌筛查项目继续致力于完善LCS工作流程，了解一些围绕LCS应该解决的有争议的问题是很重要的。在本文中，我们确定了其中的一些问题，包括低剂量CT的假阳性率、过度诊断、成本支出、少数群体的LCS差异以及生物标志物的使用。我们希望就如何解决这些争议提供清晰、潜在的解决方案和未来的方向。
期刊介绍：
Seminars in Oncology brings you current, authoritative, and practical reviews of developments in the etiology, diagnosis and management of cancer. Each issue examines topics of clinical importance, with an emphasis on providing both the basic knowledge needed to better understand a topic as well as evidence-based opinions from leaders in the field. Seminars in Oncology also seeks to be a venue for sharing a diversity of opinions including those that might be considered "outside the box". We welcome a healthy and respectful exchange of opinions and urge you to approach us with your insights as well as suggestions of topics that you deem worthy of coverage. By helping the reader understand the basic biology and the therapy of cancer as they learn the nuances from experts, all in a journal that encourages the exchange of ideas we aim to help move the treatment of cancer forward.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
